The predictors of the efficacy of pharmacological cardioversion with class III antiarrhythmic drug - nibentan in patients with persistent atrial fibrillation

被引：0
|
作者：
Bregvadze, I. [1 ]
Maykov, E. [2 ]
Sokolov, S. [2 ]
Golitsyn, S. [2 ]
Rozenshtraukh, L. [2 ]
Chazov, E. [2 ]
Pagava, Z. [1 ]
机构：
[1] Ctr Vasc & Heart Dis, Cardiol, Tbilisi, Georgia
[2] Cardiol Res & Prod Ctr, Clin Electrophysiol, Moscow, Russia
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6383
引用
收藏
页码：1374 / 1374
页数：1
相关论文
共 50 条
  • [11] Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity
    Blomstrom-Lundqvist, Carina
    Blomstrom, Per
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (04) : 671 - 679
  • [12] Antiarrhythmic efficacy of propafenone in patients with persistent atrial fibrillation
    Kurbanov, R. D.
    Zakirov, N. U.
    Azizov, Sh. K.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2011, 7 (01) : 31 - 36
  • [13] Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation
    Fujiki, Akira
    Sakamoto, Tamotsu
    Iwamoto, Jotaro
    Nishida, Kunihiro
    Nagasawa, Hidehiko
    Mizumaki, Koichi
    Inoue, Hiroshi
    CIRCULATION JOURNAL, 2006, 70 (09) : 1138 - 1141
  • [14] Electrophysiological and antiarrhythmic effects of a new class III antiarrhythmic drug nibentan in patients with paroxysmal supraventricular tachyarrhythmias
    Maykov, EB
    Bakalov, SA
    Krutanov, IB
    Golitsin, SP
    Ruda, MY
    Rosenshtraukh, LV
    Chazov, EI
    KARDIOLOGIYA, 1996, 36 (06) : 38 - 51
  • [15] Pharmacological cardioversion of atrial fibrillation: Which drugs are preferred, class IC or class III?
    Baldi, N.
    Russo, V. A.
    Di Gregorio, L.
    Morrone, V.
    Liconso, L.
    Polimeni, G.
    Cardiac Arrhythmias 2005, 2005, : 95 - 100
  • [16] Electrophysiological and antiarrhythmic effects of a new class III antiarrhythmic drug nibentan in patients with paroxysmal ventricular tachycardia
    Maykov, EB
    Baklanov, SA
    Krutanov, IB
    Golitsin, SP
    Ruda, MY
    Rosenshtraukh, LV
    Chazov, EI
    KARDIOLOGIYA, 1997, 37 (04) : 16 - 27
  • [17] Antiarrhythmic drug treatment after cardioversion of atrial fibrillation
    Vallakati, Ajay
    Sharma, Abhishek
    Lakkireddy, Dhanunjaya
    LANCET, 2012, 380 (9852): : 1467 - 1468
  • [18] Clinical study of nibentan - New class III antiarrhythmic drug .2. Efficacy in patients with supraventricular arrhythmias
    Ruda, MY
    Merkulova, IN
    Tararak, AE
    Dragnev, AG
    Golitsin, SP
    Rosenshtraukh, LV
    Chazov, EI
    KARDIOLOGIYA, 1996, 36 (06) : 28 - 37
  • [19] Predictors of Successful Chemical Cardioversion With Dofetilide in Patients With Persistent Atrial Fibrillation
    Reddy, Madhu Y.
    Janga, Pramod
    Pamulapati, Hema
    Bakhtiani, Ramchandur
    Reddy, Namratha
    Vallakati, Ajay
    Atkins, Donita
    Bommana, Sudharani
    Howard, Patricia
    Berenbom, Loren
    Lakkireddy, Dhanunjaya
    CIRCULATION, 2013, 128 (22)
  • [20] Antiarrhythmic drug treatment after cardioversion of atrial fibrillation Reply
    Kirchhof, Paulus
    Breithardt, Guenter
    Treszl, Andras
    Wegscheider, Karl
    LANCET, 2012, 380 (9852): : 1468 - 1468
12345